Receptor bias (revision 30)
Old revision·10:51, 15 Jun 2026·ReceptorRhoda
| Receptor biasReceptor pharmacology | |
|---|---|
| Also called | Biased agonism, functional selectivity |
| At the GLP-1 receptor | cAMP versus β-arrestin recruitment |
| Measured as | A bias factor, relative to a reference agonist |
| Topic infobox · conventions | |
Receptor bias, also termed biased agonism or functional selectivity, is the tendency of an agonist to favour one downstream signalling pathway over another at the same receptor. It arises because different agonists stabilise different receptor conformations, and those conformations couple differently to the available transducers.[1]
At the GLP-1 receptor the pathways usually compared are cAMP accumulation, which mediates the insulinotropic effect, and β-arrestin recruitment, which terminates G-protein signalling and drives receptor internalisation.[1]
Bias is quantified as a bias factor relative to a reference agonist, and the number depends on the reference chosen, the cell system, the readout and the incubation time. Bias factors from different publications are not comparable.[2]
The concept
[edit]Classical receptor theory treats an agonist's effect as a single efficacy applied to a single pathway. Biased agonism replaces this with a vector: an agonist has an efficacy for each transducer, and the ratio between them is what "bias" names.[2]
Quantification requires care because potency and efficacy differences that are not bias — receptor reserve differences between assays, for instance — can masquerade as it. Operational models exist to separate the two and their assumptions are not always met.[2]
The concept is real and well supported at the level of receptor conformation. What is contested is whether measured bias predicts anything clinically.[1]
At the GLP-1 receptor
[edit]An agonist producing sustained cAMP with reduced β-arrestin recruitment internalises the receptor less and maintains surface expression, which might sustain insulin secretion better over prolonged exposure. This is the therapeutic hypothesis.[1]
Evidence in humans is indirect. The bias factors reported for marketed agonists have not been shown to predict clinical differences between them, and the clinical differences that exist are adequately explained by pharmacokinetics and dose.[3]
Tirzepatide is reported to show cAMP-favouring bias at the GLP-1 receptor, and it also has a potency imbalance between the GIP and GLP-1 receptors. These are two different senses of "bias" and conflating them is a common error. See Tirzepatide.[1]
Status of the idea
[edit]Biased agonism has been a productive research programme and a disappointing translational one, at this receptor and at several others. Several biased compounds designed on the principle have failed to show the predicted clinical advantage.[2]
The honest summary is that the phenomenon is established, its molecular basis is understood, and its clinical exploitation at this target has not been demonstrated.[1]
For a reader encountering bias claims in promotional material, the useful questions are which pathways were compared, against which reference agonist, and whether any clinical endpoint was measured.[3] None of these is a property a certificate of analysis reports, and a bias claim is not a quality attribute.[4]
See also
References
- ^ a b c d e f Jones B, Buenaventura T, Kanda N, et al. "Targeting GLP-1 receptor trafficking to improve agonist efficacy." Nature Communications 9:1602 (2018). PMID 29686245.
- ^ a b c d Kenakin T, Christopoulos A. "Signalling bias in new drug discovery: detection, quantification and therapeutic impact." Nature Reviews Drug Discovery 12(3):205–216 (2013). PMID 23411724.
- ^ a b Drucker DJ. "Mechanisms of action and therapeutic application of glucagon-like peptide-1." Cell Metabolism 27(4):740–756 (2018). PMID 29617641.
- ^ United States Pharmacopeia, General Chapter <1503>, Quality Attributes of Synthetic Peptide Drug Substances.